With the recent FDA approval of alpelisib for the treatment of PIK3CA‐mutated hormone‐receptor positive metastatic breast cancer, tumor molecular profiling to identify somatic mutations and potential molecularly targeted agents is increasingly utilized in the treatment of advanced breast cancer. This evidence concerns the gene PIK3CA and breast carcinoma.